These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2355 related articles for article (PubMed ID: 27836716)

  • 21. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
    Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M; Murakami H; Horiike A; Takahashi T; Hirai F; Suenaga N; Tajima T; Tokushige K; Ishii M; Boral A; Robson M; Seto T
    J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
    Yang JJ; Zhou J; Liu SM; Li M; Zhang Z; Cheng Y; Fan Y; Pan H; Wang B; Chen G; Wang K; Jiang L; Hu Y; Shi J; Dong X; Ding C; Liu Y; Liu Z; Liao W; Li W; Wang J; Yi S; Zhao Q; Zang A; Chen Y; Cui J; Luo P; Shen X; Sun M; Wang C; Wu YL;
    Lancet Respir Med; 2024 Sep; 12(9):671-680. PubMed ID: 39059398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
    Amanam I; Gupta R; Mambetsariev I; Salgia R
    Future Oncol; 2018 Aug; 14(19):1897-1908. PubMed ID: 29451020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
    Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
    Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
    Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brigatinib: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
    Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
    J Thorac Oncol; 2024 Jun; 19(6):912-927. PubMed ID: 38280448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 118.